Matthew Wood

Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY.

Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.

Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom.

Theolytics Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Oxford, the United Kingdom.

DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom.

Macrophox Ltd. engages in the provision of research and experimental development on biotechnology. The company was founded on March 12, 2018 and is headquartered in Woodstock, The United Kingdom.

Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom.

Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom.

Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.

Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023.

Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors.

Tanarra Ventures Pty Ltd (Tanarra Ventures) is a venture capital firm subsidiary of Tanarra Group Pty Ltd founded in 2005 by John Wylie. The firm is headquartered in Melbourne, Australia.